Biohaven Ltd. · NYSE:BHVN
Biohaven — Technical Presentation (October 2026)
8 slides from Biohaven's technical presentation, Oct 6, 2026
Slide 1: Preclinical Characterization of BHV-1420: A Novel TRAP Degrader of PLA2R Autoantibodies
Preclinical Characterization of BHV-1420: A Novel TRAP Degrader of PLA2R Autoantibodies for Treatment of Membranous Nephropathy Edward deRamon, PhD Principal Investigator, Medicinal Chemistry Biohaven
Slide 2: Pathophysiology of Idiopathic Membranous Nephropathy (IMN)
Pathophysiology of Idiopathic Membranous Nephropathy (IMN) • IMN is a rare glomerular disease affecting RENAL 1.2 per 100,000 people per year, causing fatigue, KIDNEY CORPUSCLE edema, high cholesterol and low protein levels in the blood.1,2 • Driven by an autoimmune response that leads to the develo
Slide 3: Anti-PLA2R Autoantibodies Are Pathogenic in IMN
Anti-PLA2R Autoantibodies Are Pathogenic in IMN • PLA2R (phospholipase A2 receptor) is the primary BOWMAN’S CAPSULE autoimmune target in IMN. Anti-PLA2R Subepithelial immune complex deposits autoantibodies are detected in 70–80% of patients.1 • Anti-PLA2R antibodies are strongly associated with Auto
Slide 4: BHV-1420: A Highly-Selective Anti-PLA2R Autoantibody Degrader
BHV-1420: A Highly-Selective Anti-PLA2R Autoantibody Degrader Modality: Heterobifunctional degrader of anti-PLA2R autoantibodies • Leverages TRAP technology platform licensed from Prof. David Spiegel and Yale University • Exploits ASGPR pathway for internalization and degradation of extracellular pr
Slide 5: BHV-1420 Induces Ternary Complex and Mediates Anti-PLA2R Internalization
BHV-1420 Induces Ternary Complex and Mediates Anti-PLA2R Internalization Ternary Complex Formation Internalization via ASGPR-Uptake Biotin-ASGPR Fluorescently Degrader Rabbit anti-PLA2R antibody labeled PLA2R Degrader Streptavidin-Europium cryptate donor Goat anti-rabbit IgG d2 conjugate acceptor A
Slide 6: BHV-1420 Induces Rapid, Dose-Dependent Depletion of Anti-PLA2R In Vivo
BHV-1420 Induces Rapid, Dose-Dependent Depletion of Anti-PLA2R In Vivo Anti-PLA2R dosed IV at approx. conc. in patients Last timepoint taken BHV-1420 administered SC at 72 hours 1 HOUR BHV-1420 effectively depletes physiological levels of exogenous anti-PLA2R AAb in mice. 6 October 2026 ASN Kidney W
Slide 7: BHV-1420 Effectively Captures Anti-PLA2R Antibodies in IMN Samples
BHV-1420 Effectively Captures Anti-PLA2R Antibodies in IMN Samples Transfer to Clinical Diagnostic Anti-PLA2R ELISA ELISA plate Anti-PLA2R Aab TARGET BHV-1420 RISK FOR IMN BAIT LIGHT SIGNAL ANTI-HUMAN SECONDARY ANTIBODY BHV-1420 PRE-INCUBATION RECOMBINANT PLA2R Tested in a competitive ELISA format,
Slide 8: BHV-1420: A Targeted Therapy for IMN With a Novel MOA
BHV-1420: A Targeted Therapy for IMN With a Novel MOA BHV-1420 is a novel heterobifunctional TRAP degrader capable of selectively removing pathogenic anti-PLA2R antibodies from circulation. Subcutaneous administration of BHV-1420 effectively removes exogenous anti-PLA2R antibodies in a passive trans